The evidence for bile acid sequestrants (BAS) in dogs with hepatobiliary disease is limited to their use in bile acid diarrhea (BAD) secondary to chronic enteropathy, with no sourced data supporting their use in cats with hepatobiliary disease.
In dogs with chronic enteropathies, BAS are used to treat BAD arising from bile acid malabsorption (BAM). BAM occurs when decreased ileal absorptive capacity, accelerated transit time, overproduction of bile acids, or intestinal dysbiosis with loss of 7α-dehydroxylating colonic bacteria leads to excess fecal bile acids and diarrhea.Journal of Vete… Dogs treated with BAS for 5–47 months showed clinical improvement, and this response to empirically administered BAS is itself used as a diagnostic criterion for BAD, mirroring the approach used in human medicine.Journal of Vete…
The population most likely to benefit from BAS in dogs is those with inflammatory or refractory chronic enteropathy that is partially or completely refractory to other treatments, or requiring high doses of corticosteroids, with concurrent suspicion of BAM. Dogs in the reported cohort had been on stable concurrent medical treatment for a median of 396 days before BAS was added, making clinical improvement attributable to BAS rather than a late effect of prior therapy.Journal of Vete… The veterinary literature does not yet provide a standardized BAS dosing protocol or a head-to-head comparison of available agents for this indication.
BAS are not described in the sourced literature as a treatment for primary hepatobiliary disease — such as cholangitis, hepatic lipidosis, hepatobiliary neoplasia, or portosystemic shunts — in either dogs or cats.Journal of Vete…+1 Their mechanism targets fecal bile acid excess downstream of hepatic synthesis and enterohepatic circulation, not hepatocellular dysfunction or biliary infection directly.Journal of Vete…
A key limitation is that the decision to initiate BAS in the reported canine cohort was influenced by dysbiosis index or fecal bile acid results in the majority of cases, meaning this population may not represent the general chronic enteropathy population, and prospective controlled data are not yet available.Journal of Vete… The veterinary literature identifies BAS as a candidate for future prospective study in dogs with refractory non-responsive enteropathy and protein-losing enteropathy, with the potential to reduce euthanasia rates in non-responsive disease or decrease disease activity in partially responsive cases.Journal of Vete…
Would you like to know which specific bile acid sequestrant agents and doses have been reported in dogs with bile acid diarrhea?